Clinical significance of osteopontin expression in cervical cancer

被引:67
作者
Cho, HanByoul [1 ]
Hong, Soon Won [2 ]
Oh, Youn Jin [1 ]
Kim, Min A. [3 ]
Kang, Eun Suk [4 ]
Lee, Jong Min [5 ]
Kim, Sang Wun [3 ]
Kim, Sung Hoon [3 ]
Kim, Jae Hoon [1 ]
Kim, Young Tae [3 ]
Lee, Kook [1 ]
机构
[1] Yonsei Univ, Coll Med, Yongdong Severance Hosp, Dept Obstet & Gynecol, Seoul 135720, South Korea
[2] Yonsei Univ, Coll Med, Yongdong Severance Hosp, Dept Pathol, Seoul 135720, South Korea
[3] Yonsei Univ, Coll Med, Severance Hosp, Dept Obstet & Gynecol, Seoul 120752, South Korea
[4] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Dept Lab Med, Seoul 135710, South Korea
[5] Kyung Hee Univ, Coll Med, East West Neo Med Ctr, Dept Obstet & Gynecol, Seoul 134890, South Korea
关键词
osteopontin (OPN); immunostaining score; cervical cancer; diagnostic marker; prognostic marker;
D O I
10.1007/s00432-007-0351-5
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose New diagnostic markers, other than squamous cell carcinoma (SCC) antigen, are needed for the detection of cervical cancer. Osteopontin (OPN) is a candidate frequently associated with several human malignancies. The purpose of this study was to evaluate the clinical significance of OPN expression as a diagnostic and prognostic biomarker for cervical cancer. Methods Immunohistochemical staining of tissue from 97 cervical cancer cases and 22 healthy subjects was performed in order to determine the source of elevated plasma OPN levels. In addition, plasma OPN levels of 81 patients with cervical cancer, 34 patients with carcinoma in situ (CIS) of the uterine cervix, and those of 283 healthy women were measured with a commercially available solid-phase sandwich enzyme-linked immunosorbent assay (ELISA). The correlation between OPN levels and clinical features were examined and compared to SCC antigen levels in the cervical cancer cases. Results Immunohistochemical staining revealed OPN immunoreactivity in 67.0% (65/97) of cervical cancer tissues, and the immunostaining score in the cervical cancer tissue sections was 2.06 (95% CI, 1.70-2.42). There was no significant difference in immunostaining scores based on age, tumor size, and tumor stage, but higher scores (3.0 < score <= 6.0) were significantly correlated with overall survival (P = 0.002) and disease-free survival (P = 0.033). Plasma OPN levels in women with cervical cancer (mean 355.8 ng/ml) were significantly higher (P < 0.001) than those of women with CIS (mean: 185 ng/ml) and healthy controls (mean 100 ng/ml). Within the cervical cancer patients, OPN levels correlated with increasing tumor size (P = 0.008) and tumor stage (P < 0.001). The sensitivity and specificity of OPN in detecting cervical cancer was 50.6 and 95.0%, respectively (cutoff value 215.5 ng/ml). Using a combination of markers proved to bring more sensitive results than using one marker (sensitivity: 65.4%, specificity: 90.9%). High plasma OPN levels (> 215.5 ng/ml) were also correlated with disease-free survival (P = 0.038). Conclusions These results suggest that plasma OPN levels are potentially useful as a diagnostic and prognostic biomarker for cervical cancer.
引用
收藏
页码:909 / 917
页数:9
相关论文
共 34 条
[1]   Serial plasma osteopontin levels have prognostic value in metastatic breast cancer [J].
Bramwell, Vivien H. C. ;
Doig, Gordon S. ;
Tuck, Alan B. ;
Wilson, Sylvia M. ;
Tonkin, Katia S. ;
Tomiak, Anna ;
Perera, Francisco ;
Vandenberg, Theodore A. ;
Chambers, Ann F. .
CLINICAL CANCER RESEARCH, 2006, 12 (11) :3337-3343
[2]   The multifaceted roles of osteopontin in cell signaling, tumor progression and angiogenesis [J].
Chakraborty, Goutam ;
Jain, Shalini ;
Behera, Reeti ;
Ahmed, Mansoor ;
Sharma, Priyanka ;
Kumar, Vinit ;
Kundu, Gopal C. .
CURRENT MOLECULAR MEDICINE, 2006, 6 (08) :819-830
[3]   Correlation of osteopontin protein expression and pathological stage across a wide variety of tumor histologies [J].
Coppola, D ;
Szabo, M ;
Boulware, D ;
Muraca, P ;
Alsarraj, M ;
Chambers, AF ;
Yeatman, TJ .
CLINICAL CANCER RESEARCH, 2004, 10 (01) :184-190
[4]  
Crawford HC, 1998, CANCER RES, V58, P5206
[5]   Pretreatment serum squamous cell carcinoma antigen: A newly identified prognostic factor in early-stage cervical carcinoma [J].
Duk, JM ;
Groenier, KH ;
deBruijn, HWA ;
Hollema, H ;
tenHoor, KA ;
vanderZee, AGJ ;
Aalders, JG .
JOURNAL OF CLINICAL ONCOLOGY, 1996, 14 (01) :111-118
[6]  
Fedarko NS, 2001, CLIN CANCER RES, V7, P4060
[7]   MOLECULAR-CLONING AND CHARACTERIZATION OF 2B7, A RAT MESSENGER-RNA WHICH DISTINGUISHES SMOOTH-MUSCLE CELL PHENOTYPES INVITRO AND IS IDENTICAL TO OSTEOPONTIN (SECRETED PHOSPHOPROTEIN-I, 2AR) [J].
GIACHELLI, C ;
BAE, N ;
LOMBARDI, D ;
MAJESKY, M ;
SCHWARTZ, S .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1991, 177 (02) :867-873
[8]   Comparison of osteopontin expression in endometrioid endometrial cancer and ovarian endometrioid cancer [J].
Hashiguchi, Y ;
Tsuda, H ;
Bandera, CA ;
Nishimura, S ;
Inoue, T ;
Kawamura, N ;
Berkowitz, RS ;
Mok, SC .
MEDICAL ONCOLOGY, 2006, 23 (02) :205-212
[9]   Osteopontin as a potential diagnostic biomarker for ovarian cancer [J].
Kim, JH ;
Skates, SJ ;
Uede, T ;
Wong, KK ;
Schorge, JO ;
Feltmate, CM ;
Berkowitz, RS ;
Cramer, DW ;
Mok, SC .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2002, 287 (13) :1671-1679
[10]   Vascular endothelial growth factor gene and protein:: strong expression in thyroiditis and thyroid carcinoma [J].
Klein, M ;
Picard, E ;
Vignaud, JM ;
Marie, B ;
Bresler, L ;
Toussaint, B ;
Weryha, G ;
Duprez, A ;
Leclère, J .
JOURNAL OF ENDOCRINOLOGY, 1999, 161 (01) :41-49